Bone injection for CT scans: tiny study tests safety
NCT ID NCT01531686
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study looked at whether CT contrast dye can be safely and effectively delivered through a needle placed in the upper arm bone (intraosseous access) instead of a vein. Only 8 adults who already had such access were enrolled. The study was terminated early, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CT contrast dye delivered via intraosseous access
- What this could lead to
- If successful, this could show that injecting CT contrast dye through a bone (intraosseous) is a safe and effective option when IV access is not possible.
- What could go wrong
- This was a very small study (only 8 people) that was terminated early, so results are limited and may not apply broadly. The procedure carries risks like infection or dye leakage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
8 people
The number who actually took part.
- Start date
-
Mar 2012
- Finished
-
Jan 2014
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients who have received proximal humerus intraosseous vascular access as standard of care via the EZ-IO 45 mm needle set and require Computed Tomography (CT) examination
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 years or older * Has received intraosseous (IO) vascular access at the proximal humerus insertion site via EZ-IO 45 mm needle set, as standard of care * Requires Computed Tomography (CT) examination with contrast media delivery via proximal humerus intraosseous catheter, as standard of care * Cognitively and physically able to give written consent to participate in the study or is obtained from a Legally Authorized Representative (LAR) Exclusion Criteria: * Fracture in target bone, or significant trauma to the site * Excessive tissue and/or absence of adequate anatomical landmarks in target bone * Infection in target area * IO insertion in past 24 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone * Allergy to contrast media * Imprisoned * Pregnant * Requires English language translation other than Spanish * Has received proximal humerus IO access with an IO catheter other than the EZ-IO 45 millimeter (mm) needle set system * Has existing proximal humerus IO access using the EZ-IO 45 mm needle set but IO catheter is mal-positioned or dislodged
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Patients with intraosseous vascular access requiring computed tomography (CT) exam are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grand Strand Regional Medical
Myrtle Beach, South Carolina, 29572, United States
-
Maricopa Medical Center
Phoenix, Arizona, 85008, United States
-
Olive View UCLA Medical Center
Sylmar, California, 91342, United States
-
Shands Critical Care Center and Cancer Hospital
Gainesville, Florida, 32608, United States